QLT Eligard Sales Suspended For Two Months; Aczone Could Launch In 2007
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
U.S. sales of QLT/Sanofi-Aventis' Eligard will be suspended for two months due to a patent dispute with rival leuprolide implant Lupron marketer TAP, despite a court ruling that allows for sales to continue